ANTISOMA? Lasset uns mal darüber entscheiden!

Probleme mit der Umschalttaste so müssen wir ihm zugestehen, das heute ein sehr guter Umsatz(Frankfurt Parkett) Zustande gekommen ist. 17.01 -1.200.000 wurden gehandelt.
zwar gabe es eine sehr geringen Kursabweichung(10 %) aber man muss hiergegen halten, das die Aktie in schlechten Zeiten(wir alle wissen, das sie zwar noch nicht vorbei sind,) nicht gelitten hat. Im Gegenteil sie ist Trendverkehrt marschiert.

Vielleicht sollten wir nicht alle GROSSCHREIBER mit Pushern beschimpfen. Ich glaube Ecevit hat eine recht gute Empfehlung rausgegeben und versucht nicht direkt den Kurs zu pushen.

Auf jeden Fall werde ich mich eindecken..

ciao Leute. q

Und zwar zu 4,75 nur geringe Stückzahl. Nach so einem Anstieg sollte man auch die Risiken nicht aus den Augen verlieren. Nur sollte e. nicht dauernd Großbuchstaben verwenden, dann wärs schon ok.

Der Aktionär hat sie (glaub ich) mal empfohlen, um die 2.80

Habe das erstemal nach einer Empfehlung im Aktionär geordert. Muss zugeben, dass bis jetzt alles zum besten läuft. Der Herr Förtsch macht schon seine Hausaufgaben sehr gut. Bei Vertex war meine Verärgerung schon groß, habe Aufsprung verpasst. Nun rollt der Zug eben bei Antisoma. In der Krebsforschung scheint Antisoma eine wirkliche Perle zu sein. Schaut Euch doch mal ganz genau die Homepage an, einfach ausgezeichnet die Produktvielfalt.
Auf die ersten 100% in diesem Jahr im Depot.

sie ist wirklich sehr interessant. heute noch einsteigen?
war schon ganz schön viel umsatz *grübel*
ihr macht mir den mund wässrig....
krebsforschung hört sich wirklich auch gut an.
steigt ihr noch ein???

(p.s.: ich finde förtsch übrigens gut)

                                    mechanism to fend off insects, as a potential weapon against cancer.

                                    According to promising data to be presented at the British Association’s Festival of Science meeting,
                                    “Creating Sparks,” which opens in London today, the scientists have mimicked a natural method of
                                    protection used by plants like the African potato and the hydrangea. The plants contain an enzyme, called
                                    linamarase, which is capable of generating cyanide when animals or insects cause damage to the plant,
                                    thereby deterring further attacks. Scientists have attached the enzyme to a cancer-seeking antibody
                                    capable of recognising a protein found only in certain cancers. The molecule formed from the combined
                                    antibody and enzyme has been shown to generate small amounts of cancer-killing cyanide when presented
                                    with a separately administered, natural, non-toxic chemical substance.

                                    “We have demonstrated that this system is able to specifically kill tumour cells by cyanide intoxication,” says
                                    Dr Mahendra Deonarain of Imperial College’s Department of Biochemistry in London.

                                    Although at an early stage, the method -- known as AGENT (Antibody Guided Enzyme Nitrile Therapy) --
                                    could eventually lead to a safe and effective way of treating cancer which acts only on cancerous cells and
                                    leaves healthy tissue unharmed. Unlike existing cancer-killing treatments, which can cease to be effective as
                                    cells develop resistance, cancer cells are unable to resist the effects of cyanide.

                                    Despite the deadly nature of cyanide, the amount generated by the technique is only sufficient to kill the
                                    specific cancer cell targeted by the combined enzyme-antibody molecule. A natural enzyme produced in the
                                    human liver will detoxify any cyanide that leaks away from the tumour.

                                    “At this stage of the research, we have yet to determine the optimum molecule. However, we have
                                    demonstrated the concept of cyanide-targeted tumour cell killing and are actively working to develop a
                                    higher potency system able to act on a variety of cancer types,” Deonarain will tell the conference.

                                    Professor Agamemnon Epenetos, Chief Scientific Officer at Antisoma plc added: “This is a fascinating use
                                    for a natural defence mechanism, one of several projects that Antisoma is funding as it seeks to broaden its
                                    early stage cancer pipeline.”

                                    - END –


                                    Enquiries

                                    Glyn Edwards, Chief Executive Office Tel: +44 (0)20 8799 8200
                                    Val Tate, Head of Investor Relations

                                    David Yates, Jonathan Birt Tel: +44 (0)20 7269 7156
                                    Financial Dynamics

                                    Notes

                                    Antisoma is a biopharmaceutical company developing novel products for the treatment of cancer. The
                                    Company’s strategy is to use its drug development experience to produce safer and more effective tumour
                                    targeting therapies for commercialisation by pharmaceutical partners. The Company’s core competence is
                                    the conduct of rapid, cost-effective, semi-virtual drug development. Antisoma acquires the rights to promising
                                    new product candidates through partnerships with internationally recognised academic or cancer research
                                    institutions. These include the lead product candidate, Theragyn, which was licensed from the Imperial
                                    Cancer Research Fund.

                                    The Company’s particular focus is the use of monoclonal antibodies to target tumour cells while leaving
                                    healthy cells unharmed. The lead product, Theragyn, is currently in a Phase III study as adjuvant treatment
                                    for ovarian cancer, with designated Orphan Drug status in the US. Abbott Laboratories have a worldwide
                                    exclusive licence to develop, market and sell the product.

                                    Antisoma’s therapeutic product candidates are:

                                    Product candidate Indication(s) Current stage of development
                                    Theragyn Ovarian cancer Phase III
                                    Gastric cancer Phase II
                                    Therex Breast cancer Phase I
                                    TheraFab Lung cancer Pre-clinical
                                    AngioMab Brain cancer Pre-clinical
                                    Other solid tumours Pre-clinical
                                    Targeted apoptosis Cancer Pre-clinical
                                    Immunotherapy Cancer Pre-clinical

wäre vorsichtig mit dem Einstieg.
Antisoma ist nahe an den 100% in meinem Depot und dieses in kürzester Zeit.
Es gibt genug Beispiele, wo es weiter ging, aber es gab auch den Verlust.
Die Phantasie und die Marktkapitalisierung ( bei ca 600 Millionen Euro )sprechen für Antisoma, dagegen ist Medigene vom Wert her ein Bluechip.
Dagegen spricht der rasante Anstieg ohne adhoc.
Das Handelsvolumen ist gigantisch.
Maeuserich, würde nur mit stoploss der 10% unterm Einstiegskurs ordern, man weiß nie, ....entweder rauf oder runter....

das ist es eben!
man weiß es nie!
der chart sieht nicht schlecht aus.
und ebenso das heutige volumen und der rasante anstieg ohne jegliche meldung.

ich glaub einfach an qiagen, singulus, poet und antisoma...